Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Oct 18, 2019 10:43 PM EDT

News Releases

Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019

October 1, 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 1, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that multiple maralixibat

Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference

September 26, 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 26, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

August 28, 2019

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today reported financial results for the

Mirum Pharmaceuticals Announces Pricing of Initial Public Offering

July 17, 2019

FOSTER CITY, Calif. , July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price

Events

2019 Cantor Global HC Conference

Oct 4, 2019 at 10:40 AM EDT

Click here for webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu